@ljgfitness's TRT bloodwork analysis, fact-checked
Quick answer
The creator describes running testosterone at a dose well above replacement range for eight weeks and presents elevated hematocrit, hemoglobin, and red blood cell count as a manageable side effect. Erythrocytosis at supraphysiologic testosterone doses is a documented cardiovascular risk factor, with therapeutic phlebotomy being a legitimate but medically supervised intervention. The methylene blue recommendation for hematocrit management lacks clinical evidence and should not be followed based on this video.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @ljgfitness actually say?
The creator shared blood work taken eight weeks into what they describe as a supraphysiologic testosterone cycle, running "300 kilograms of tests" (clearly a verbal slip for 300 milligrams). Their main concern was elevated hematocrit, hemoglobin, and red blood cell count. To address it, they recommended hydration, methylene blue (sold via their bio link), and therapeutic phlebotomy. They also commented on creatinine, liver enzymes, and lipids, framing most results as "pretty optimal."
One thing worth flagging immediately: this person describes themselves as being on TRT and then "upping" the dose substantially. That is not TRT by any clinical definition. That is a performance-enhancing drug cycle. The framing matters, because it shapes how 21,000 viewers interpret the risks involved.
Does the science back this up?
On hematocrit elevation from testosterone, yes, the evidence is solid. Erythrocytosis is one of the most consistently documented adverse effects of testosterone therapy, with rates varying by formulation and dose.
Research backs this clearly. Coviello et al. (2008, Journal of Clinical Endocrinology and Metabolism) found dose-dependent increases in hematocrit among men receiving testosterone, with supraphysiologic doses producing the most pronounced effects. The Endocrine Society guidelines flag hematocrit above 54% as a threshold requiring dose reduction or treatment pause. Therapeutic phlebotomy is a legitimate intervention used in clinical practice for this purpose.
On creatinine elevation from high protein intake and resistance training, that is also supported. Baxmann et al. (2008, Kidney International) confirmed that dietary protein and muscle mass significantly influence serum creatinine, making it a poor standalone marker for kidney function in athletes. So far, so reasonable.
Where things get shakier is the methylene blue recommendation.
What did they get wrong (or right)?
Let's start with what they got right. Hematocrit monitoring during testosterone use is genuinely important. Phlebotomy is a real, clinically used intervention. The lipid advice, tracking diet and doing cardio, is consistent with evidence that aerobic exercise attenuates HDL suppression from anabolic steroid use (Hartgens and Kuipers, 2004, Sports Medicine). These are not nothing.
Now, what they got wrong. The methylene blue recommendation is a problem. The creator says it "helps with blood thickening" and directs viewers to a purchase link in their bio. There is no peer-reviewed clinical evidence that methylene blue reduces erythrocytosis or lowers hematocrit in this context. Methylene blue has legitimate medical uses, including methemoglobinemia treatment, but selling it as a hematocrit remedy to a fitness audience while monetizing the link is misleading at best.
The framing of this as "TRT blood work" when the dose described is supraphysiologic also misrepresents the risk profile. Viewers using actual replacement doses should not assume these results apply to them in the same way. And describing liver enzymes as "pretty optimal" while casually mentioning oral steroid use pre-workout without advising against it is a gap worth calling out.
What should you actually know?
Elevated hematocrit from testosterone use is not a minor inconvenience. Hematocrit above 52-54% raises the risk of thromboembolic events including stroke and deep vein thrombosis. Glueck et al. (2014, Clinical and Applied Thrombosis/Hemostasis) documented increased clotting risk in men on testosterone with erythrocytosis. This deserves more than a casual mention between lipid results.
Phlebotomy works, but it should be supervised. Donating blood is one way some men manage this, though donation centers have varying policies on accepting blood from people using androgens.
Creatinine alone tells you very little in this population. eGFR calculated using creatinine will be artificially lowered in people with high muscle mass, which can create false alarms or, conversely, mask early kidney stress. Cystatin C is a more reliable marker and worth requesting.
- Anyone running supraphysiologic testosterone should be under medical supervision, not self-managing based on TikTok blood work reviews.
- Methylene blue has no established role in managing testosterone-induced erythrocytosis. Do not buy it for this purpose.
- "Optimal" is doing a lot of work in this video. Results that look acceptable at eight weeks can deteriorate significantly with continued use.
The bottom line
This creator is more transparent than most in this space, and some of what they say is factually grounded. But calling a supraphysiologic cycle "TRT," monetizing an unproven supplement recommendation, and glossing over the cardiovascular stakes of elevated hematocrit are real issues. This is not a template for managing your own blood work.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @ljgfitness's TRT bloodwork analysis, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@ljgfitness's TRT bloodwork analysis, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The creator describes running testosterone at a dose well above replacement range for eight weeks and presents elevated hematocrit, hemoglobin, and red blood cell count as a manageable side effect.
FormBlends verdict
The creator describes running testosterone at a dose well above replacement range for eight weeks and presents elevated hematocrit, hemoglobin, and red blood cell count as a manageable side effect. Erythrocytosis at supraphysiologic testosterone doses is a documented cardiovascular risk factor, with therapeutic phlebotomy being a legitimate but medically supervised intervention. The methylene blue recommendation for hematocrit management lacks clinical evidence and should not be followed based on this video.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes running testosterone at a dose well above replacement range for eight weeks and presents elevated hematocrit, hemoglobin, and red blood cell count as a manageable side effect. Erythrocytosis at supraphysiologic testosterone doses is a documented cardiovascular risk factor, with therapeutic phlebotomy being a legitimate but medically supervised intervention. The methylene blue recommendation for hematocrit management lacks clinical evidence and should not be followed based on this video.
- Hematocrit above 54% is the Endocrine Society's threshold for clinical intervention during testosterone therapy, and supraphysiologic doses reach this faster than replacement doses.
- Therapeutic phlebotomy is a real, evidence-backed intervention for erythrocytosis, but it should be supervised by a clinician, not self-managed based on social media advice.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Hematocrit above 54% is the Endocrine Society's threshold for clinical intervention during testosterone therapy, and supraphysiologic doses reach this faster than replacement doses.
- Therapeutic phlebotomy is a real, evidence-backed intervention for erythrocytosis, but it should be supervised by a clinician, not self-managed based on social media advice.
- Methylene blue has no established clinical evidence for reducing testosterone-induced hematocrit elevation. Purchasing it for this purpose based on a TikTok recommendation is not supported by science.
- Serum creatinine is an unreliable kidney function marker in high-protein, high-muscle-mass individuals. Cystatin C or creatinine-based eGFR with clinical context gives a clearer picture.
- Doses described in this video are supraphysiologic and outside the definition of TRT, which typically targets low-normal physiologic testosterone levels. The risk profile is meaningfully different.
- Glueck et al. (2014, Clinical and Applied Thrombosis/Hemostasis) documented elevated thromboembolic risk in men on testosterone with erythrocytosis, including stroke and DVT risk.
- Casual oral anabolic steroid use described as an occasional pre-workout carries significant hepatotoxicity risk. Liver enzymes appearing normal at eight weeks does not rule out cumulative damage.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
ljgfitness · TikTok creator
21.0K views on this video
Brief Bloodwork analysis. Share your thoughts in the comments guys. #trt #testosterone #enhanced #menshealth #bloodtest
Sources & references
- [1]Coviello et al. (2008)
- [2]Baxmann et al. (2008)
- [3]Glueck et al. (2014)
- [4]Hartgens and Kuipers, 2004
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by ljgfitness, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.